Periodic Paralysis: Attacks of Weakness Tied to Potassium Shifts

A person goes to bed well and wakes unable to lift their legs. Hours later the strength is back, and blood tests look ordinary again. That is the pattern of periodic paralysis: repeated attacks of limp weakness, set off by things as everyday as a large meal or a rest after hard exercise, with the amount of potassium in the blood often moving during the attack. Most forms are inherited faults in the tiny gates that let charged particles in and out of muscle cells. One form is acquired, and comes from an overactive thyroid.

The Potassium for Muscle Function page explains how potassium keeps a muscle fiber ready to fire and gives a short overview of these conditions. This page goes further, into the separate forms, the genes, the long exercise test, the drug trials and label facts, the danger of giving too much potassium, the heart rhythm risks of Andersen-Tawil syndrome, and what happened to thyrotoxic attacks once the thyroid was treated.

Table of Contents

  1. What Happens in the Muscle During an Attack
  2. The Four Forms
  3. The Genes in Plain Words
  4. Attack Triggers That Have Been Reported
  5. How It Is Diagnosed, Including the Long Exercise Test
  6. What the Dichlorphenamide Trials Found
  7. What the Dichlorphenamide Label States
  8. Acetazolamide and the Part the Gene Plays
  9. Potassium and the Hazard of Overshoot
  10. Heart Rhythm Hazards in Andersen-Tawil Syndrome
  11. The Thyrotoxic Form and What Thyroid Treatment Did in Reports
  12. Permanent Weakness Later in Life
  13. What Is Not Known
  14. Key Research Papers
  15. Connections
  16. Featured Videos

What Happens in the Muscle During an Attack

A muscle fiber is like a charged battery. Its inside sits at a negative voltage, and a nerve signal works by briefly flipping that voltage. The sodium-potassium pump and a set of potassium and sodium channels keep the charge in place.

A 2025 study from Foy and colleagues opens with the shared feature of all forms: attacks of weakness are “precipitated by depolarization of muscle,” which means the fiber loses its negative charge. The 2018 expert review by Statland and colleagues explains why this causes weakness. A fiber that stays partly discharged switches its sodium channels off, and without those channels it can no longer answer the nerve. The nerve is firing, but the muscle does not respond. That is why these attacks are limp, with no stiffness or spasm as their main feature.

The change in blood potassium differs from form to form. The same 2025 study used a computer model, tested against lab recordings, to ask why. It found that small net movements of potassium and sodium, building up over hours, decided whether a fiber would lose its charge. In that model, ion levels shifted over hours before a fiber failed.

These conditions are rare. A national count in England in 2011 found, as a minimum, 0.13 people per 100,000 with genetically confirmed hypokalemic periodic paralysis, 0.17 per 100,000 with hyperkalemic periodic paralysis and 0.08 per 100,000 with Andersen-Tawil syndrome. Those figures count only people whose diagnosis was confirmed by a gene test at the national service.

Back to Table of Contents

The Four Forms

Three forms are inherited, and the 2018 review describes them as autosomal dominant, meaning one altered copy of the gene is enough. Their attacks usually start in the first or second decade of life. The fourth form is tied to an overactive thyroid. The numbers on age, attack length and potassium in this section come from the full text of the 2018 review.

Hypokalemic periodic paralysis (low potassium during attacks)

Blood potassium falls during the attack as potassium moves out of the blood and into the muscle. The first attack usually comes between ages 5 and 35, and attacks are most frequent between ages 15 and 35. They last hours and sometimes days, and can come daily, weekly or monthly. A 2026 review adds that they often occur at night or early in the morning. People in this group do not have the muscle stiffness seen in the high-potassium form.

Hyperkalemic periodic paralysis (high or normal potassium during attacks)

Attacks begin in the first decade of life in about half of patients. They tend to be shorter and more frequent than low-potassium attacks, and often begin in the morning and last up to 2 hours. Blood potassium rises in many attacks but stays normal in some, so a normal result during an attack does not exclude this form. About half of patients have muscle stiffness between attacks. Eating or being given potassium can set off an attack or deepen one that has started.

Andersen-Tawil syndrome (weakness, heart rhythm changes, physical features)

This form affects more than skeletal muscle. It is described as a triad of attacks of weakness, heart rhythm changes, and physical features such as low-set ears, widely spaced eyes, a small jaw, a curved fifth finger, and joined second and third toes. Potassium during attacks can be low, high or normal. Not everyone shows all three parts. In a French cohort of 35 patients, the full triad appeared in 42.9%, and a 2021 review puts it at about 60%. The same French cohort reported heart abnormalities in 65.7%, physical features in 71.4% and periodic paralysis in 80%, and periodic paralysis was significantly more common in men. Potassium during attacks was low in 53.6%. On average the diagnosis came 14.4 years late, which the wide mix of symptoms helps explain. The 2021 review also describes mild learning difficulties in some people.

Thyrotoxic periodic paralysis (low potassium with an overactive thyroid)

The attacks resemble the inherited low-potassium form, but they occur during hyperthyroidism and stop once it is controlled. A 2006 review describes it as a common complication of hyperthyroidism in Asian men that is increasingly seen in Western countries. In a Hong Kong registry of 994 cases over two decades, 93.66% of patients were male. It has also been reported in women and in older people: a 2020 case series describes it in a young Caucasian man and in two Caucasian women, one elderly and one middle-aged.

Back to Table of Contents

The Genes in Plain Words

Each gene below is a recipe for one kind of gate in the cell wall of a muscle fiber. A misspelling in the recipe gives a gate that leaks, sticks or fails to work.

A gene result does not settle everything. In a series of 226 patients from 127 families, mutations were found in about two thirds of families. Those without a found mutation had a less typical picture: older age at onset, no diet trigger, and none of the vacuoles (small cavities in the fiber) seen in other patients' muscle under a microscope. A 2026 genetics review notes that inheritance can be incomplete and that some cases are sporadic, with no family history.

Back to Table of Contents

Attack Triggers That Have Been Reported

A 2021 literature review by Welland and colleagues searched three decades of papers for triggers related to food and exercise. It found no observation or intervention studies testing whether lifestyle changes alter attacks. What exists is case reports, expert opinion and retrospective case studies, and the authors call the evidence weak. With that limit stated, these are the triggers reported most often.

One proposed explanation for the link with carbohydrate comes from research on the thyroid form: insulin is among the hormones that a 2012 review says reduce the flow of potassium out of muscle. The 2018 review also says people with the low-potassium form are at increased risk of weakness around anesthesia.

Back to Table of Contents

How It Is Diagnosed, Including the Long Exercise Test

The 2018 review describes a sequence. It starts with the story: age at first attack, length of attacks, triggers and family history. When the story fits, the review's authors use genetic testing as the first step. When no mutation is found, the support comes from a documented low or high potassium during attacks, or from an abnormal long exercise test.

The difficulty is timing. A blood test is only useful if drawn during an attack, and attacks often end before anyone tests. That is what the long exercise test helps with, because it provokes a very small attack, in one hand muscle, on a day when the person feels well.

How the long exercise test works

As described in the full text of the 2018 review, the person repeatedly contracts the small muscle at the edge of the hand that moves the little finger outward, for 5 minutes, in 15-second bursts with short rests. A technician stimulates the nerve to that muscle and records the size of the electrical response, then repeats this every minute or two for 40 to 60 minutes afterward. In periodic paralysis the response shrinks after the exercise. Older tests that provoked a whole-body attack have largely been replaced by it.

How well it performs

Ruling out other causes

The supportive criteria in the 2018 review for the low-potassium form require excluding other causes of low potassium, including kidney and adrenal problems, thyroid dysfunction, renal tubular acidosis and diuretic or laxative misuse. Barium poisoning is another cause of sudden low potassium with weakness. The 2006 thyroid review states that a thyroid function test is what separates the thyrotoxic form from the other low-potassium forms. For Andersen-Tawil syndrome the review adds an electrocardiogram showing a long QT or QU interval, and heart monitoring over 24 hours.

The 2018 review also lists features that point elsewhere: prominent pain or numbness during attacks, changes in consciousness, double vision, drooping eyelids or trouble swallowing, and reflexes that remain in a paralyzed limb. Thyrotoxic attacks are often first mistaken for Guillain-Barré syndrome, according to the 2025 narrative review.

Back to Table of Contents

What the Dichlorphenamide Trials Found

Dichlorphenamide is a carbonic anhydrase inhibitor, a type of medicine that makes the urine lose bicarbonate and potassium and makes the blood slightly more acid. A 2016 review notes that it was the first drug approved in the United States for primary periodic paralysis. The trial gave people new to the drug 50 mg twice a day. People already on the drug kept their dose, and people coming from acetazolamide were set at 20% of their acetazolamide dose. Dose cuts were allowed for side effects, and the mean dose at week 9 was 94 mg a day in the low-potassium group and 82 mg a day in the high-potassium group, according to the label.

The two 9-week trials, published in 2016

The 35-week crossover study, reported on the label

In this study each person spent time on both the drug and placebo. In the low-potassium group (42 people), sudden intolerable worsening occurred in 2 people on the drug and 11 on placebo (p = 0.02). In the high-potassium group (31 people, including people with paramyotonia congenita, a related stiffness condition), the drug gave 2.3 fewer attacks a week than placebo (p = 0.006).

The one-year extension

After the 9-week phase, the study continued with 52 more weeks in which participants took the drug openly. Of 63 adults who finished the blinded phase, 47 (74.6%) completed 61 weeks. Median weekly attacks fell from baseline by 1.00 in those on the drug from the start and by 0.63 in those who began on placebo. The analysis was post hoc and open label, so everyone knew they were on the drug. The paper's disclosures state that one author was an employee of the company then selling the drug and that the company funded the writing assistance. Side effects, mainly tingling and thinking problems, usually first appeared within a month and often resolved when the dose was reduced.

Adolescents

In a crossover study with 7 adolescents aged 10 to 17, 5 could be assessed for benefit. Their median weekly attacks fell by 0.96 on the drug and 0.57 on placebo, close to the adult pattern of 0.83 and 0.24. Rash was the most common side effect in adolescents, in 2 of 6. Numbers this small can only describe, not prove.

Back to Table of Contents

What the Dichlorphenamide Label States

These facts come from the generic dichlorphenamide tablet label on DailyMed (revised January 2026).

Back to Table of Contents

Acetazolamide and the Part the Gene Plays

Acetazolamide, a related carbonic anhydrase inhibitor, has been the most commonly used treatment for hypokalemic periodic paralysis since 1968. A 2011 study collected results from 74 genotyped patients in the United Kingdom and China. Only 46% (34 of 74) reported benefit. The gene mattered: 31 of 55 people with CACNA1S mutations responded, against 3 of 19 with SCN4A mutations. People whose mutation replaced an amino acid with glycine were the least likely to benefit.

The 2018 review adds that some patients, especially with certain SCN4A mutations, got worse on acetazolamide, and that 3 patients who worsened on it later responded to dichlorphenamide. The 2011 study was retrospective, and its authors wrote that randomized trials are still needed to test the link between genotype and response. The 2018 review lists kidney stones as a concern with this class of drugs, reporting them in 3 of 20 people on long-term acetazolamide for myotonia.

A different approach is being explored in the lab. In muscle taken from mice with a low-potassium sodium channel mutation, the diuretic bumetanide prevented weakness and restored force during an established attack, and it worked better than acetazolamide in those tests. It did not help muscle from mice with the high-potassium form. Making the surrounding fluid more concentrated, which activates the transport system bumetanide blocks, made that muscle weaker, and the authors raised dehydration as a possible aggravating factor. These are results in isolated mouse muscle, not in patients.

Back to Table of Contents

Potassium and the Hazard of Overshoot

This is the fact most likely to surprise. In the low-potassium forms, the body has not run out of potassium. The 2018 review states that total body potassium is not depleted, because the potassium has moved from the blood into the muscle, so correcting the blood level is not the same as refilling an empty store. Its treatment table calls for caution with quick potassium doses because of overshoot. The 2006 thyroid review says the same of the thyrotoxic form: the low level comes from a sudden shift into cells and not from a deficiency. When the attack ends, that potassium comes back out, on top of whatever was given.

The clearest numbers come from a 1999 hospital series of 24 episodes of thyrotoxic periodic paralysis in 19 patients:

A 2026 case report shows how severe this can be. Potassium replacement in one patient with thyrotoxic periodic paralysis led to dangerous hyperkalemia needing aggressive treatment to lower potassium, along with medicines to support blood pressure. High potassium can stop the heart, as described on the Potassium and Heart Rhythm and Potassium Toxicity and Muscle Weakness pages.

The opposite hazard is also real. The 2006 review states that prompt potassium prevents serious heart and lung complications, because very low potassium is itself dangerous. A 2020 case series records a man with malignant ventricular arrhythmias from severe low potassium who needed defibrillation. In the same series, two patients stayed low despite potassium chloride, and full recovery took up to day 5. Care sits between both dangers, and the 2018 review notes that giving potassium through a vein usually means a hospital stay with heart monitoring.

Two more facts from that review matter here. In the hyperkalemic form, potassium can set off or worsen an attack, so the same remedy that helps one form harms another. And in the low-potassium form, the review reports that giving potassium in glucose or saline solutions may worsen the weakness. These facts are why knowing the form, or at least the potassium level during an attack, carries so much weight.

Weakness reaching the breathing muscles, fainting, and a racing or irregular heartbeat during an attack are signs hospitals treat as urgent. The case reports above tie respiratory failure and arrhythmia to these attacks.

Back to Table of Contents

Heart Rhythm Hazards in Andersen-Tawil Syndrome

This is the one inherited form with a direct heart risk, and the 2018 review calls it potentially fatal. Some people first come to attention because of palpitations or a faint and not because of weakness. The heart's rhythm in this condition has a distinctive look. A 2021 review describes QT intervals, a measure of how long the heart takes to reset, that are normal or only slightly long, with a longer interval called QU, and it calls bidirectional ventricular tachycardia the hallmark rhythm. Torsades de pointes, a dangerous rhythm linked to long QT syndrome, is rare.

The sources do not fully agree on how dangerous this is. The 2018 review says arrhythmias are common while fainting and cardiac arrest are rare, and the two cohorts below give fuller numbers.

Fewer extra beats on a monitor and fewer life-threatening events are not the same outcome, and the 2020 and 2025 findings measure these different things. They do not settle which treatment prevents cardiac arrest. Decisions about these medicines rest with a cardiologist who knows the condition.

Treatments for the muscle can collide with treatments for the heart. The 2018 review reports that some rhythm drugs, including lidocaine, mexiletine, propafenone and quinidine, may worsen the weakness. It also cautions about inhaled salbutamol, which can ease high-potassium attacks but may provoke arrhythmias, about thiazide diuretics, which can lower potassium and lengthen the QT interval, and about medicines known to prolong the QT interval. It describes yearly heart tracing and 24-hour monitoring even in people with a KCNJ2 mutation and no symptoms.

Back to Table of Contents

The Thyrotoxic Form and What Thyroid Treatment Did in Reports

The thyroid form is often the first sign that anyone has hyperthyroidism. In a Thai cohort of 2,964 people with hyperthyroid Graves' disease treated over 35 years, 63 (2.1%) had thyrotoxic periodic paralysis, 60 of them men, and in 82.5% the paralysis was the first presentation of the disease. Their median blood potassium during an attack was 2.1 mmol/L. The usual signs of hyperthyroidism can be subtle or missing, according to the 2006 review. In the Hong Kong registry, the male rate in 2021 was 1.18 per 100,000 person-years and the female rate 0.13, and nearly all patients were admitted to hospital, for a median stay of 2 to 3 days.

What stands out in this literature is what happened after the thyroid was brought under control.

The Thai cohort shows why the word “control” matters. No patient in remission after radioiodine had another attack, and nearly all who received radioiodine became hypothyroid, meaning an underactive thyroid. Of the 36 treated first with antithyroid drugs, followed for a mean of 9.1 years, 10 (27.8%) relapsed after stopping, 6 had further paralysis, and only 8 (22.2%) went into remission. The authors concluded in favor of radioiodine or thyroidectomy to prevent relapse and further attacks, although no one in the cohort had surgery. This is a retrospective comparison in which treatment was not randomly assigned.

Until the thyroid is under control, reports describe nonselective beta blockers, a class that includes propranolol. The 2006 review says they can lessen attacks and prevent recurrence. These findings come from reviews, case records and a retrospective cohort, and none of the papers read for this page is a randomized trial of thyroid treatment for these attacks.

Back to Table of Contents

Permanent Weakness Later in Life

The name of the condition suggests attacks that come and go. For many people it does not stay that way. A 2024 review describes a change around age 40, when the episodic attacks give way to permanent, progressive weakness and muscle disease. The 2018 review's full text says more than 80% of people over 40 with the hyperkalemic form have permanent weakness, and one third develop chronic progressive muscle disease.

A 2026 review of the low-potassium form describes four patterns: no symptoms, attacks without permanent weakness, attacks with permanent weakness, and permanent weakness with no attacks at all. That last group has no attacks to point toward the diagnosis. Vacuoles, small cavities that generally contain glycogen, are present in the muscles of all patients with this form, and imaging shows fat replacing muscle more over time, alongside falling strength. The review states that no treatment is currently available for this permanent weakness. In the French Andersen-Tawil cohort, 45.7% had permanent weakness in the muscles closest to the trunk, mild and stable or slowly progressive over decades.

The most personal numbers come from an online survey of 66 patients over age 41, with a mean age of 60:

A self-reported online survey can be weighted toward people with more severe disease, so these are not rates for everyone with the condition. The Hypokalemia and Muscle Weakness page covers weakness from ordinary low potassium, a separate problem.

Back to Table of Contents

What Is Not Known

Back to Table of Contents

Key Research Papers

  1. Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018;57(4):522-530. PubMed PMID: 29125635
  2. Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, et al. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86(15):1408-1416. PubMed PMID: 26865514
  3. Sansone VA, Johnson NE, Hanna MG, Ciafaloni E, Statland JM, Shieh PB, et al. Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis. Muscle Nerve. 2021;64(3):342-346. PubMed PMID: 34129236
  4. Foy BD, Dupont C, Walker PV 2nd, Denman K, Engisch KL, Rich MM. Mechanisms underlying the distinct K+ dependencies of periodic paralysis. J Gen Physiol. 2025;157(3):e202413610. PubMed PMID: 39903205
  5. Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472-5. PubMed PMID: 23516313
  6. Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63(9):1647-55. PubMed PMID: 15534250
  7. Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105(4):511-9. PubMed PMID: 11371347
  8. Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140(1):88-98. PubMed PMID: 20074522
  9. Lin SH, Huang CL. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol. 2012;23(6):985-8. PubMed PMID: 22460532
  10. Luo M, Liu B, Xu J, Meng D. Clinical features and advances in the genetics of periodic paralysis. PeerJ. 2026;14:e20840. PubMed PMID: 41800133
  11. Welland NL, Hæstad H, Fossmo HL, Giltvedt K, Ørstavik K, Nordstrøm M. The Role of Nutrition and Physical Activity as Trigger Factors of Paralytic Attacks in Primary Periodic Paralysis. J Neuromuscul Dis. 2021;8(4):457-468. PubMed PMID: 33646174
  12. Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56(5):650-61. PubMed PMID: 15389891
  13. Simmons DB, Lanning J, Cleland JC, Puwanant A, Twydell PT, Griggs RC, et al. Long Exercise Test in Periodic Paralysis: A Bayesian Analysis. Muscle Nerve. 2019;59(1):47-54. PubMed PMID: 29752813
  14. Ribeiro A, Suetterlin KJ, Skorupinska I, Tan SV, Morrow JM, Matthews E, et al. The long exercise test as a functional marker of periodic paralysis. Muscle Nerve. 2022;65(5):581-585. PubMed PMID: 34817893
  15. Greig SL. Dichlorphenamide: A Review in Primary Periodic Paralyses. Drugs. 2016;76(4):501-7. PubMed PMID: 26941026
  16. Ciafaloni E, Cohen F, Griggs R. Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults. Pediatr Neurol. 2019;101:43-46. PubMed PMID: 31570296
  17. Matthews E, Portaro S, Ke Q, Sud R, Haworth A, Davis MB, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology. 2011;77(22):1960-4. PubMed PMID: 22094484
  18. Wu F, Mi W, Cannon SC. Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis. Neurology. 2013;80(12):1110-6. PubMed PMID: 23427324
  19. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med. 1999;159(6):601-6. PubMed PMID: 10090117
  20. Pisano TJ, Merical B, Wang Z, Levine JM. Rebound Hyperkalemia in Hypokalemic Thyrotoxic Periodic Paralysis. Neurohospitalist. 2026;16(1):78-82. PubMed PMID: 40470174
  21. Bilha S, Mitu O, Teodoriu L, Haba C, Preda C. Thyrotoxic Periodic Paralysis-A Misleading Challenge in the Emergency Department. Diagnostics (Basel). 2020;10(5):316. PubMed PMID: 32443393
  22. Villar-Quiles RN, Sternberg D, Tredez G, Beatriz Romero N, Evangelista T, Lafôret P, et al. Phenotypical variability and atypical presentations in a French cohort of Andersen-Tawil syndrome. Eur J Neurol. 2022;29(8):2398-2411. PubMed PMID: 35460302
  23. Pérez-Riera AR, Barbosa-Barros R, Samesina N, Pastore CA, Scanavacca M, Daminello-Raimundo R, et al. Andersen-Tawil Syndrome: A Comprehensive Review. Cardiol Rev. 2021;29(4):165-177. PubMed PMID: 32947483
  24. Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, et al. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. Europace. 2013;15(12):1805-11. PubMed PMID: 23867365
  25. Mazzanti A, Guz D, Trancuccio A, Pagan E, Kukavica D, Chargeishvili T, et al. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. J Am Coll Cardiol. 2020;75(15):1772-1784. PubMed PMID: 32299589
  26. Mann TD, Yoruk A, Neves RA, Bergman AT, Bos MJ, van der Werf C, et al. Flecainide for the Treatment of Andersen-Tawil Syndrome. JACC Clin Electrophysiol. 2025;11(7):1511-1518. PubMed PMID: 40372332
  27. Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006;91(7):2490-5. PubMed PMID: 16608889
  28. Li GH, Tang CM, Li RS, Ge GM, Kung AW, Tan KC, et al. Twenty-year trend of thyrotoxicosis and thyrotoxic periodic paralysis: a population-based cohort study. Eur Thyroid J. 2025;14(5):e250220. PubMed PMID: 40911544
  29. Karndumri K, Thewjitcharoen Y, Chatchomchuan W, Porramatikul S, Krittiyawong S, Wanothayaroj E, et al. Impact of first-line treatment choice on long-term outcomes of hyperthyroid Graves' disease patients with thyrotoxic periodic paralysis. J Clin Transl Endocrinol. 2020;21:100235. PubMed PMID: 32953456
  30. Sehmer B, Arnason T. Pop-provoked paralysis: silent Graves' disease presenting as thyrotoxic periodic paralysis. BMJ Case Rep. 2012;2012:bcr2012006292. PubMed PMID: 23203166
  31. Alrashidi FS. Thyrotoxic Periodic Paralysis (TPP): A Comprehensive Review with Regional Insights from the Middle East. Cureus. 2025;17(12):e98814. PubMed PMID: 41523487
  32. Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31(2):126-33. PubMed PMID: 23097604
  33. Suetterlin K, Law S, Arnold WD. Periodic paralysis across the life course: age-related phenotype transition and sarcopenia overlap. Front Neurol. 2024;15:1507485. PubMed PMID: 39777323
  34. Bossola M, Senatore A, Di Stasio E. Permanent weakness and myopathy in hypokalemic periodic paralysis. Acta Myol. 2026;45(1):19-24. PubMed PMID: 41954147

PubMed Topic Searches

  1. PubMed: Hypokalemic periodic paralysis
  2. PubMed: Hyperkalemic periodic paralysis
  3. PubMed: Andersen-Tawil syndrome
  4. PubMed: Thyrotoxic periodic paralysis
  5. PubMed: Long exercise test in periodic paralysis
  6. PubMed: Dichlorphenamide in periodic paralysis

Back to Table of Contents

Connections

Back to Table of Contents